Stein E A
Medical Research Laboratories, Christ Hospital Cardiovascular Research Center, Cincinnati, Ohio 45219.
Scand J Clin Lab Invest Suppl. 1990;198:3-8.
Coronary atherosclerotic disease remains the major cause of mortality and morbidity in western societies. Despite significant reductions in the incidence of death associated with the disorder over the last 30 years, especially in the United States, there is an urgent need to identify more clearly the underlying causative agents so that primary and secondary prevention programs can be implemented. A number of lipid parameters such as total and LDL-cholesterol have withstood long-term evaluation, and have met all the criteria necessary to designate them as playing a causative role in coronary atherosclerosis. These two parameters, especially LDL-cholesterol, is now the focus of a number of public health initiatives in various countries. The role of HDL-cholesterol is still not yet certain, while that of triglycerides is still clouded. A host of newer lipid associated (apolipoprotein) parameters are currently under investigation and it will be a number of years before any of these could be designated in the same class as LDL-cholesterol. Among the apolipoprotein measurements, Apo B appears to be the most promising in terms of meeting requirements to elevate it from risk factor to causative agent.
冠状动脉粥样硬化性疾病仍然是西方社会死亡和发病的主要原因。尽管在过去30年中,尤其是在美国,与该疾病相关的死亡率显著下降,但仍迫切需要更明确地确定潜在的致病因素,以便实施一级和二级预防计划。一些脂质参数,如总胆固醇和低密度脂蛋白胆固醇,已经经过了长期评估,并且符合将它们认定为在冠状动脉粥样硬化中起致病作用所需的所有标准。这两个参数,尤其是低密度脂蛋白胆固醇,现在是各国许多公共卫生举措的重点。高密度脂蛋白胆固醇的作用仍不确定,而甘油三酯的作用仍不明确。许多与脂质相关的新参数(载脂蛋白)目前正在研究中,在这些参数中的任何一个能够被认定与低密度脂蛋白胆固醇属于同一类别之前,还需要数年时间。在载脂蛋白测量中,就满足将其从危险因素提升为致病因素的要求而言,载脂蛋白B似乎最有前景。